Transdiagnostic cognitive behavioural treatment and the impact of co-morbidity:an open trial in a cohort of primary care patients by Kristjánsdóttir, Hafrún et al.
        
Citation for published version:
Kristjánsdóttir, H, Salkovskis, PM, Sigurdsson, BH, Sigurdsson, E, Agnarsdóttir, A & Sigurdsson, JF 2016,
'Transdiagnostic cognitive behavioural treatment and the impact of co-morbidity: an open trial in a cohort of
primary care patients', Nordic Journal of Psychiatry, vol. 70, no. 3, pp. 215-223.
https://doi.org/10.3109/08039488.2015.1081404
DOI:
10.3109/08039488.2015.1081404
Publication date:
2016
Document Version
Peer reviewed version
Link to publication
University of Bath
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. May. 2019
1 
 
Transdiagnostic Cognitive Behavioural Treatment and the impact 
of comorbidity: An open trial in a cohort of primary care patients  
Running title: Transdiagnostic CBT: Impact of comorbidity 
 
Hafrún Kristjánsdóttir, Psychologist 
University of Iceland/ Reykjavik University/Landspítali-The National University Hospital of 
Iceland, 
 
Professor Paul M. Salkovskis, 
University of Bath, 
 
Baldur Heiðar Sigurðsson, Psychologist 
Landspítali-The National University Hospital of Iceland/Reykjavik University, 
 
Professor Engilbert Sigurdsson, 
University of Iceland/Landspítali-The National University Hospital of Iceland, 
 
Agnes Agnarsdóttir, Psychologist 
 Landspítali-The National University Hospital of Iceland, 
 
and 
Professor Jón Friðrik Sigurðsson, 
University of Iceland/Reykjavik University/Landspítali-The National University Hospital of 
Iceland. 
 
 
Correspondence author 
Hafrún Kristjánsdóttir 
Address: Menntavegur 1 
Tel: 003548941713 
Fax: 003545995201 
E-Mail: hafrunkr@ru.is 
 
 
 
 
 
 
2 
 
Background: The development of initiatives to improve access to psychological therapies 
has been driven by the realisation that untreated anxiety and depression are both very 
common and costly to individuals as well as society. Effective and efficient treatments, 
mostly in the form of cognitive behavioural therapies (CBT), can be used in ways which 
enhance their acceptability and accessibility. Up to date, numbers of group therapies have 
been developed to improve cost efficiency, but in spite of growing interest in transdiagnostic 
approaches, group therapies have so far mostly been diagnosis specific.  
Aims: This study aimed at evaluating a brief transdiagnostic cognitive behavioural group 
therapy (TCBGT) designed to treat both anxiety and depression among patients in primary 
care. 
Method: The participants were 287 adult patients in primary care with diagnoses of 
depression and/or anxiety disorders. They underwent a five week TCBGT. A mixed design 
ANOVA was used to evaluate differential effects of treatment according to diagnostic groups 
(anxiety vs. depression) and number of diagnoses (comorbidity). 
Results: Pre-post differences were significant and the treatment was equally effective for 
both anxiety disorders and depression. Number of diagnoses did not affect the outcome. 
Conclusions: The study indicates feasibility of the brief transdiagnostic group therapy for a 
wide range of mood- and anxiety disorders in primary care. The results indicate that low 
intensity, brief transdiagnostic group therapies may be a feasible way to improve access to 
psychological therapies for a large number of patients. 
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Background 
The development of initiatives to improve access to psychological therapies has been driven 
by two main factors. Firstly, the realisation that untreated anxiety and depression are both 
very common and costly to individuals as well as society. Secondly, effective and efficient 
treatments, mostly in the form of cognitive behavioural therapies (CBT), can be used in ways 
which enhances their acceptability and accessibility (1–4). The systematic application of CBT 
to a range of common mental health problems has been found to be both clinically effective 
and cost-effective (2,5–8). 
At lower intensities of treatment, there remain important unresolved issues on how best to 
deliver the range of programmes which constitute CBT for different diagnostic groups and 
services such as the Improving Access to Psychological Therapies (IAPT) in the United 
Kingdom (UK). The IAPT project is based on allocating diagnoses, then offering diagnosis-
specific interventions in which the practitioners have been appropriately trained and for 
which they receive supervision (9). However, such an approach remains costly, and it has 
more recently been suggested that the development of purposeful transdiagnostic CBTs, 
(TCBT), which could be used across a range of anxiety disorders and depression, might 
further improve efficiency and accessibility of evidence-based treatments (10–12). However, 
there is as yet only limited evidence for the efficacy of such approaches.  
Research has time and again demonstrated the efficacy of CBT in the treatment of both 
depression and anxiety disorders (5,8) and therefore clinical guidelines propose that the first 
treatment of choice should be CBT delivered in primary rather than secondary care (13–16). 
Efficiency in treatment can be achieved through the use of group therapies, particularly in the 
earlier stages of “stepped care”. Such therapies have been found to be effective in the context 
of diagnostically homogenous samples (17). However, setting up such services in primary 
4 
 
care can be difficult and impractical because gathering people with the same kind of mental 
disorders, such as Obsessive Compulsive Disorder (OCD), into OCD groups, can take too 
long time (12,18). This can lead to an unacceptable time lag from referral or worse still, these 
specific groups may never even take off. Furthermore, many patients in primary care are 
diagnosed with more than one mental disorder at the same time, or on average 2.1 disorders 
per patient (19) and specific CBTs do not necessarily benefit patients with multiple diagnoses 
as much as those with one disorder (20). Even though there is evidence to suggest that if 
patients are treated for their main diagnosis, the rate of co-morbid diagnoses decreases 
following treatment (21,22). 
 
Since 2005, patients with different common disorders in primary care in Iceland have 
been offered a brief cognitive behavioural group-therapy, i.e. transdiagnostic therapy. TCBT 
has been defined as CBT that applies similar, or the same, underlying treatment principles for 
different psychiatric disorders (23–25) since the same or similar underlying maintenance 
processes are assumed (24,26) Proposed maintenance processes targeted in the treatment 
studied are cognitive biases and interpretation errors, fuelled by negative core beliefs, 
dysfunctional attitudes and assumptions. McEvoy, Nathan and Norton (11) argue on a priori 
grounds that transdiagnostic treatment is the most cost effective form of treatment for 
primary care, although there is as yet little evidence for such a claim. The extent to which 
economies of scale are balanced by loss of definition in treatment is as yet unknown and 
needs to be researched.  
The majority of published TCBT outcome studies have been carried out on 
transdiagnostic anxiety groups where patients with various anxiety disorders are treated with 
the same protocol (27–32). There have been five outcome studies where patients with anxiety 
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and/or depression were treated in transdiagnostic groups. Manning et al. and Hooke and Page 
(33) examined the outcome of an intensive two week-long transdiagnostic cognitive 
behavioural group therapy (TCBGT) for patients with what they refer to as “neurotic” or 
“affective” mental disorders, apparently corresponding to anxiety and depressive disorders, 
respectively. Statistically and clinically significant improvements were found on all measures 
and these were maintained for a year, with no statistically significant differences between 
“neurotic” and “affective” groups. McEvoy and Nathan (30) evaluated a 10 week TCBGT for 
patients with depression and/or anxiety disorders. Outcomes were good and comparable for 
all groups of patients, depressive, anxious, and those patients suffering from both depression 
and anxiety disorders. Wuthrich and Rapee (34) examined the effectiveness of a 12-week (24 
hours) TCBGT for older adults. A significant difference was found on the mean improvement 
between participants who underwent TCBGT and participants on a wait list on self-report 
measures of anxiety and depressive symptoms. Finally Ejeby et al. (35) examined the 
effectiveness of a 12-week (24 hours) TCBGT for people with common mental health 
problems in primary care compared with Care As Usual (CAU) and Multi Modal Intervention 
(MMI). Participants in the MMI group improved significantly more than those in the TCBGT 
and CAU groups, but the TCBGT participants improved significantly more than CAU 
participants.  
In transdiagnostic treatment, it is proposed that if patients are encouraged to apply general 
strategies, for example using thought charts, to rate their emotional experience, they will be 
more able to cope with the different problems they face. In that respect transdiagnostic 
treatment may be more efficient in treating co-morbid conditions than disorder-specific 
treatment (32,36,37).  Questions have been raised though, regarding the possible limitations 
of TCBT in treating highly comorbid patients. Ericson, Janeck and Tallman (38) for instance 
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believe that the approach is not suitable for people with more than two comorbid disorders, 
but no evidence supports their claims. 
Aims 
In the present study the outcome of a brief (five week) TGCBT was examined for a 
range of anxiety disorders and depression. The aim of this open trial was to test the following 
three hypotheses regarding treatment feasibility and effectiveness in a routine clinical setting 
in primary care: 1) patients are responsive to the brief TGCBT relative to their own baseline, 
2) the treatment is effective for patients with a wide range of common mental disorders, 3) 
types of symptoms (depressive vs. anxiety symptoms) are differently affected by the 
treatment and 4) the treatment is more effective for those who have diagnoses of one or two 
disorders than more than two disorders. 
 
 
 
Material and Methods 
Settings and participants 
This study is based on data from the first two years of a project were the main aim was to 
increase access to psychological therapies in primary care in Iceland. TCBGT was offered in 
six primary health care centres based on referrals from General Practitioners (GPs). Criteria 
for referral were signs of emotional problems based on GP’s clinical evaluation and being 
over 18 years of age. Exclusion criteria for treatment were: 1) presence of symptoms 
suggesting current psychotic condition as evaluated by a GP or a clinical psychologist 
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administering the MINI-International Neuropsychiatric Interview (M.I.N.I.) (see below), 2) 
current self-reported substance abuse or substance dependence, as evaluated by a GP or a 
clinical psychologist administering the M.I.N.I., and 3) obvious signs of dementia or another 
generalized cognitive impairment.  A control group was also recruited including patients who 
received treatment as usual, but the attrition rate was very high so  the data was not used in 
this analysis. 
In total 441 participants attended the treatment during these two years, 77 men 
(17.5%) and 364 women (82.5%). The mean age was 39.7 years (SD 13.1, range 18 – 88 
years).  
To be included in the study, patients had to meet the diagnostic criteria for one or 
more mood and/or anxiety disorder according to the M.I.N.I. and to have scores above cut-off 
on at least one of the following instruments, the Beck Depression Inventory, the Beck 
Anxiety Inventories (BDI-II and BAI) and the Clinical Outcomes in Routine Evaluation – 
Outcome Measure (CORE-OM) (see description of all measures below). This gave a total of 
287 participants of whom 281 attended at least one treatment session. All subsequent 
intention-to-treat analyses were based on this number.  
 
************** Figure 1 about here**************** 
 
As Figure 1 shows, 281 patients were included in the data analysis, 41 men (14.6%) and 240 
women (85.4%). The mean age was 38.5 years (SD=12.89, range 18 – 88 years). Only 6.4% 
had some prior experience of CBT, but forty-six per cent were receiving psychotropic drugs 
whilst in treatment. While stabilisation with medication was not an inclusion criteria, GPs were 
instructed not to increase the medication prior to or during treatment to control as best as possible for 
potential gains of medication. The average number of diagnoses per participant was 2.0 
8 
 
disorders (SD=1.0, range: 1-6 disorders).  Of the 283 participants, 92 had one diagnosis, 92 
had two diagnoses, 54 had three diagnoses, 25 had four diagnoses and 20 had more than four 
diagnoses. 
 
Measures 
The primary outcome measure, CORE-OM, was pre-defined to test for changes in general 
psychopathology. The scale is divided into four subscales, well-being (I have felt O.K. about 
myself), function (I have felt terribly alone and isolated), problems (I have felt tense, anxious 
or nervous) and risk (I have been physically violent to others). The CORE-OM gives two 
total scores. The mean of all items indicates general distress and the mean of all items except 
the risk items (non-risk items) is also a measure of general distress, but less polluted by the 
risk items and thus considered to be a clearer indication of distress on a group basis, since 
patients can suffer a lot without being suicidal. The items are scored on a Likert scale ranging 
from 0 – 4 and for easy comparison between scales and total scores the means of the total 
scale, non-risk items and all subscales are computed. Each outcome reported is therefore on a 
scale from 0 – 4. Benchmark for “improvement in CORE-OM is reduction of 0.5 points or 
more (39) The non-risk items were used as the primary outcome measure for this study. The 
reliability and validity of the Icelandic translation of the CORE-OM is good and it seems to 
be feasible for trials of transdiagnostic treatments (40). The CORE-OM was administered in 
the intake interview, the last therapy session, and at three months follow-up.  
Secondary outcome measures, pre-defined to test changes in general 
psychopathology, included the BDI-II (41) and the BAI (42) The reliability and validity of the 
Icelandic translations of the BDI-II and the BAI are good (43,44). The BAI and the BDI-II 
were administered in the intake interview, the first, third and the last therapy session, and at 
three month follow up.  
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The M.I.N.I. (45), which is a short structured diagnostic interview of mental disorders, 
was administered in the intake interview. The Icelandic version of the M.I.N.I. has not yet 
been extensively studied although one preliminary study gives support to its validity (46). 
The English version of the M.I.N.I. has shown excellent reliability (47). Table 1 lists the 
M.I.N.I. diagnostic categories and frequencies for each category.   
 
***************Table 1 about here***************** 
Procedure 
If a GP believed, after a clinical evaluation, that a patient had mild to moderate depression 
and/or anxiety and did not meet the exclusion criteria, the patient could be referred to the 
brief transdiagnostic cognitive behavioural group therapy.  
All the patients referred to the therapy were thoroughly assessed, by a clinical psychologist 
that delivered the treatment, in an intake interview with the M.I.N.I. and the psychological 
scales. If the patient did not meet the exclusion criteria he or she was offered the opportunity 
to participate.  All the psychologist that ran the treatment were working at the psychiatry 
ward at Landspitali – The National University Hospital of Iceland and were trained CBT 
therapists.  Their work experience as clinical psychologist ranged between one and 20 years.  
The psychologist were supervised byan  experienced psychologist who was also one of the 
authors of the treatment manual. The supervisor assesed the treatment fidelity through the 
psychologist‘s self report. 
 
Permission for the study was obtained from the National Bioethics Committee in 
Iceland (VSNb2005090003/03-15) and the study was approved by the Icelandic Data 
Protection Authority (S2602/2005). 
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Intervention 
 The brief transdiagnostic cognitive behavioural group treatment offered in the study had 
been in development for a few years at the outpatient unit at the Mental Health Services at 
Landspitali – The National University Hospital of Iceland. The goal of the treatment strategy 
developed was to include components that disorder specific treatment protocols had in 
common.  
The treatment was delivered by two qualified clinical psychologists at each primary 
care setting weekly for two hours for five weeks. The psychologists were all working at the 
Mental Health Services at Landspítali – The National University Hospital of Iceland. They 
were all thoroughly familiarised with the treatment manual and the psychoeducational 
material at Landspítali were they delivered the treatment at least once with another therapist 
already experienced with the manual, before delivering it in Primary Care. In addition, all 
therapists involved in the study were supervised on a peer group basis once a week in order to 
monitor treatment fidelity. Mean group size was 14.86 patients (range 7 – 25). In the effort to 
increase public access to CBT in primary care it was deemed important to reach a large 
number of patients. To that end the treatment was mainly structured around psychoeducation 
to manage larger groups. The upper group size limit could therefore be as high as 25 although 
in some centres it was limited by the size of the facilities. The main components of the 
treatment are shown in Table 2.  
 
*********Table 2 about here******** 
  
Statistical analysis 
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Four analyses using a mixed model ANOVA were carried out, all of them testing the first 
hypothesis (that patients respond positively to the TCBGT relative to their own baseline). The 
first analysis was a 4x2 repeated measures intention-to-treat (ITT) ANOVA, to assess 
changes in distress following treatment as measured by the CORE-OM non-risk items in the 
different diagnostic groups grouped in the following way; 1) Major Depressive Disorder 
(depression), 2) any anxiety disorders covered in the M.I.N.I. (anxiety), 3) Major Depressive 
Disorder with any comorbid anxiety disorder covered in the M.I.N.I. (depression plus 
anxiety) and 4) any two or more co-occurring anxiety disorders covered in the M.I.N.I. 
(anxiety plus anxiety). Diagnostic group (anxiety, anxiety plus anxiety, depression and 
depression plus anxiety) was the grouping variable and the pre-post comparison was the 
within-subjects factor. This model tested the first and the second hypotheses with the primary 
outcome measure. The second model was a 4x2x2 repeated measures ITT ANOVA, to assess 
changes in depression and anxiety symptoms as measured by the BDI-II and the BAI 
following treatment. The diagnostic group (anxiety, anxiety plus anxiety, depression and 
depression plus anxiety) was the grouping variable, depression and anxiety symptoms (i.e. 
scores on the BDI-II and the BAI) was the first within-subjects’ factor (where the participants 
depression scores were compared to their anxiety scores in order to find if patients respond 
differently on the two scales) and the pre-post comparison the second within-subjects factor. 
This model tested the first, second and third hypothesis with the secondary outcome 
measures. 
To test the fourth hypothesis, that the treatment is more effective for patients with one 
or two disorders than patients with more than two disorders, these two analyses were 
modified by grouping the participants by number of diagnoses rather than diagnostic 
categories. Two groups were compared, one consisting of participants with one or two 
diagnoses, the other one with patients with three or more diagnoses. The resulting analyses 
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were a 2x2 and a 2x2x2 repeated measures ANOVAs both testing the first and fourth 
hypothesis with the primary and the secondary outcome measures respectively and the 2x2x2 
repeated measures ANOVA assessing the third hypothesis again in relation to comorbidity 
instead of type of diagnosis. 
Effect sizes were calculated with the formula: d = (Mpre – Mpost )/ σpooled (48) 
 
Results 
Descriptive statistics 
Table 3 shows descriptive statistics, 95% CI and effect sizes, for the total sample and by both 
grouping variables used in the study. Participants who were diagnosed with both depression 
and anxiety scored higher on all the pre-treatment measures (BDI-II: 28.74, BAI: 23.46, 
CORE-OM: 2.16) than those who were diagnosed with anxiety alone, depression alone and 
those with two or more anxiety disorders (anxiety + anxiety) (>0.001), except for those with 
two or more anxiety disorders on BAI (p>0.05). Participants diagnosed with anxiety scored 
lowest on the BDI-II (17.32) and the CORE-OM non-risk items (1.47) at baseline and those 
diagnosed with depression only scored lowest on the BAI (16.40). Those diagnosed with 
three or more disorders scored higher on all outcome measures than those diagnosed with 
fewer disorders, both before (p<0.001) and after treatment (p<0.001).  After the treatment 
28% of participants had improved according to the CORE-OM criteria for improvement.  
 
*****Table 3 here****** 
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Diagnostic groups   
CORE-OM non-risk items 
The ITT 4x2 repeated measures ANOVA for the CORE-OM non-risk items detected 
significant main effects of time (F[1,277]=34.3, p<0.001) and group (F[3,277]=18.25, 
p<0.0001), but no interaction between group and time (F[3,277]=0.98, p=0.4). This suggests 
that the treatment leads to significant reduction of distress, that comorbidity groups differed 
in overall level of distress both before and after treatment, but did not respond differentially 
to treatment. The results therefore support hypotheses 1 and 2. 
BDI-II and BAI 
The ITT 4x2x2 ANOVA detected significant main effects of depression and anxiety 
symptoms, as measured by the BDI-II and the BAI (F[1,277]=20.93, p<0.001), and time 
(F[1,277]=69.53 p<0.001), but no interaction between diagnostic groups and time 
(F[3,277]=0.89, p=0.44) or depression and anxiety symptoms and time (F[1,277]=1.76, 
p=0.19). This suggests that depression and anxiety symptoms changed following treatment 
and the different diagnostic groups were similarly responsive to treatment. Participants 
responded similarly on both depression (BDI-II) and anxiety (BAI) symptoms. These 
findings suggest that the patients were responsive to the treatment (supporting hypothesis 1), 
and that the treatment was effective for patients with a wide range of common mental 
disorders (supporting hypothesis 2) and finally that the different types of symptoms as 
measured with BDI-II and BAI responded similarly to the treatment (rejecting hypothesis 3) 
 
Effect sizes 
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Effect sizes for all group differences and all measures were calculated (Table 3). Effect sizes 
ranged from 0.29 to 0.85, smallest for the participants with anxiety on the CORE–OM non-
risk items and the largest for the participants with depression on the BDI-II. 
 
Number of diagnoses  
CORE-OM non-risk items 
In order to test whether the treatment was more effective for patients with two or fewer 
diagnoses than patients with more than two comorbid diagnoses (hypothesis 4) an ITT 2x2 
ANOVA was carried out. The results showed significant main effects of time 
(F[1,279]=54.64, p<0.001), but no interaction between group and time (F[1, 279]=1.14, 
p=0.29). The results support of hypothesis 1 but reject hypothesis 4. This suggests that 
distress changed during the treatment and that participants diagnosed with three or more 
disorders were similarly responsive to treatment as participants with one or two disorders. 
BDI-II and BAI 
The ITT 2x2x2 ANOVA detected significant main effects of depression and anxiety 
symptoms (F[1,279]=31.86, p<0.001) and time (F[1,279]=97.69 p<0.001), but no interaction 
between number of diagnoses and time (F[3,279]=0.33, p=0.57) or depression and anxiety 
symptoms and time (F[1,279]=2.54, p=0.112). This suggests that depression and anxiety 
symptoms changed following treatment and that participants with three or more disorders 
were similarly responsive to treatment as participants with one to two disorders. Participants 
responded similarly on both depression (BDI-II) and anxiety (BAI) symptoms. These 
findings suggest that the patients were responsive to the treatment (supporting hypothesis 1) 
and that the treatment was equally effective for patients with more than two disorders as it 
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was for patients with two disorders or fewer (not supporting hypothesis 4) and that the 
participants responded similarly to types of symptoms measured (not supporting hypothesis 
3). 
 
Discussion 
The patients receiving the brief TGCBT improved on all measures following treatment, 
relative to their own baseline and regardless of their main diagnoses. There was no evidence 
that participants with more than two diagnoses benefitted less than those with two or fewer 
diagnoses.  
These results are comparable to the findings of McEvoy and Nathan (49) in terms of 
responses across diagnoses. At least for the depressive patients the effect sizes were large 
(0.85) as in the McEvoy and Nathan study (1.20). However, in the present study the treatment 
groups were larger and the treatment was briefer.  
The present study differed from the previous studies in statistical analyses, because 
we used Intention-to-treat analysis (ITT), with the last observation carried forward, in 
contrast to per protocol analysis in the previous studies. ITT is a more conservative method 
used specifically in order to minimize the risk of over-interpreting treatment effects. Recent 
evidence from studies, where both weekly and pre-post measures were used, indicates that 
non-availability of post-treatment measures does not occur at random, with the effect size for 
participants who complete both pre- and post-treatment data being almost double that of 
those who did not provide end of treatment data (9). This underscores the importance of ITT 
in estimating treatment effects. 
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Erickson, Janeck and Tallman (18) argued, from the perspective of clinical 
experience, that transdiagnostic treatment would not be feasible for patients diagnosed with 
more than two distinct disorders and should therefore not be administered to such patients. 
However, the results from the present study suggest that participants diagnosed with three or 
more disorders were similarly responsive to the treatment as participants with one or two 
disorders. The scores on the psychological scales, however, were somewhat higher in the 
group diagnosed with more than two disorders, both before and after treatment. The post 
treatment scores were in the moderate range of depression so the patients were not entirely 
symptom free. It could therefore be argued that such patients may still need additional 
booster sessions or longer and perhaps more specific treatment.  
Clark and Taylor (38) have suggested that transdiagnostic therapy may be a good 
choice to start with and that such an approach is consistent with the IAPT “low intensity” 
strategy. It is the nature of transdiagnostic treatments to teach generic skills, and those skills 
may prove helpful when patients are referred to more disorder-specific treatments. This 
however is an empirical question that needs to be evaluated further. 
A final point is worth noting. When the treatment effects in the present study are 
compared with regard to types of symptoms, there are signs of the treatment having a greater 
impact on depressive symptoms than symptoms of anxiety. This may not come as surprise 
when the protocol is examined in detail (see Table 2). The protocol is rather focused on 
automatic thoughts and re-evaluations, partly in the context of cognitive biases, although 
behavioural activation is also encouraged in the psychoeducation. There is not, however, a 
prominent part dealing with behavioural experiments and testing these thoughts and 
evaluations, which is assumed to be an important ingredient in order to deal with threat 
appraisals and avoidance and other behavioural characteristics of anxiety. It is therefore of 
interest to modify the protocol to ensure that anxiety symptoms will be better targeted.  
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Clearly the study was an open trial with patients selected for referral by their GPs in the 
simplest way possible. Caution is therefore needed in terms of sampling (for example unequal 
gender balance affecting the generalizability), absence of a control group (limiting the 
internal validity) and unequal group sizes (reducing the power of the statistical analyses 
conducted). In particular the insignificant interaction effects should be interpreted with 
caution.  Also, it is worth mentioning that the patients’ comorbid symptoms were quite severe and 
therefore they are likely to demonstrate to some degree of regression towards the mean. The results 
should be interpreted with that in mind.  However, it is also in the nature of the services involved 
that retention in the study was particularly high and the evidence indicates that almost all 
patients showed good response to rather low doses of treatment. It is in the nature of the way 
the treatment was embedded in the primary care that participants are likely to be 
representative of the population as a whole. Furthermore, attrition rate may have been so low 
because it was being offered in the context of the main healthcare provider and almost all 
alternatives were less accessible.  
As the measures used to evaluate the transdiagnostic treatment were themselves 
general measures (i.e. non-specific to diagnosis), we do not know what impact the treatment 
had on disorder specific symptoms beyond depressive symptoms. It is possible that general 
distress changed as a result of the therapeutic interventions, but symptoms and behaviours, 
very specific to individual diagnoses, such as rituals in OCD, avoidance in Posttraumatic 
Stress Disorder (PTSD) or worries in GAD, may or may not have changed. Future research 
on transdiagnostic approaches must examine these factors to ensure that treatment properly 
meets the needs of all diagnoses.  
Conclusion  
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It can be tentatively conclude that the brief 5 week TCBGT is effetive, there is evidence that 
the treatment is effective for both anxiety disorders and depression and that number of 
diagnoses does not affect outcome. However, it is not clear whether the treatment has effect 
on disorder specific symtoms because these were not measured.  
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Table 1. The M.I.N.I. diagnostic categories and frequencies in pooled clinical sample.  
Disorder Time frame Frequencies (%) 
Major depressive episode Current (2 weeks), Recurrent 45 
30 
MDE with melancholic features Current (2 weeks) 19 
Dysthymia Current (2 years) 18 
Suicidality Current (past month) 44 
Manic episode Current, Past 2 
Hypomanic episode Current, Past 2 
Panic Current (past month), 
Lifetime 
8 
Agoraphobia Current 3 
Social phobia Current (past month) 31 
OCD Current (past month) 7 
PTSD Current (past month) 7 
Alcohol dependence Past 12 months 8 
Alcohol abuse Past 12 months 1 
Substance dependence (Non alcohol) Past 12 months 2 
Substance abuse (Non alcohol) Past 12 months 0 
Psychotic Current 
 Lifetime 
0 
Mood disorder with psychotic features Current 1 
Anorexia nervosa Current (past 3 months) 0 
Bulimia nervosa Current (past 3 months) 2 
GAD Current (past 6 months) 44 
Antisocial personality disorder Lifetime 3 
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Table 2. The treatment‘s main objectives and homework assignments.   
Session Main objectives Homework 
1. Introduction to group rules. 
Psychoeducation about depression, anxiety 
and basic principles of CBT 
Personal treatment goals. 
2. Review of samples of homework. 
Introduction to the relationship between 
thoughts, emotions and behaviour and 
negative automatic thoughts. 
 
Three levels thought chart 
and daily activity chart 
Aim: To identify distorted 
and negative automatic 
thoughts. 
3. Review of samples of homework. 
Introduction to cognitive distortions and the 
concept of alternative thoughts. 
 
Thought chart.  
Aim: To identify distorted 
thoughts and generate 
alternative thoughts. 
4. Review of samples of homework. 
Work with alternative thoughts as well as 
introduction of underlying assumptions and 
core beliefs. 
 
Thought chart.  
Aim: To identify distorted 
thoughts and generate 
alternative thoughts. 
5. Review of samples of homework. 
Review the techniques that have been 
introduced.  
Address barriers to the application of the 
techniques. 
Relapse prevention. 
 
 
Follow up 
booster session. 
3 months post 
treatment. 
Open discussion.  
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Table 3. Descriptive statistics, confidence intervals, and effect sizes on all the outcome measures by diagnostic groups and number of diagnoses. 
  BDI-II BAI CORE-non risk items 
Group 
 
95%CI 
  
95% CI 
  
95% CI 
   Mean (SD) Lower Upper Cohen's d Mean (SD) Lower Upper Cohen's d Mean (SD) Lower  Upper  Cohen's d 
By diagnostic group 
            Anxiety1 (N=52)    
 
        
Pre 17.32 (7.07) 14.96 19.67 
0.42 
17.52 (9.05) 14.45 20.59 
0.56 
1.47 (0.49) 1.31 1.63 
0.29 
Post 14.06 (8.56) 11.12 17.00 12.53(8.88) 9.57 15.5 1.31 (0.63) 1.12 1.5 
Anxiety+ anxiety2 (N=25) 
   
 
   
 
   
 
Pre 18.60 (6.62) 15.2 22.00 
0.68 
17.56 (10.95) 13.13 21.99 
0.39 
1.64 (0.61) 1.41 1.87 
0.42 
Post 13.88  (7.28) 9.64 18.12 13.58(9.63) 9.29 17.85 1.39 (0.59) 1.12 1.7 
Depression3 (N=59) 
   
 
   
 
   
 
Pre 24.70 (9.25) 22.49 26.91 
0.85 
16.40 (10.46) 13.51 19.28 
0.48 
1.84 (0.62) 1.58 1.93 
0.63 
Post 16.39 (10.25) 13.63 19.15 11.61 (9.69) 8.82 14.39 1.49 (0.49) 1.22 1.62 
Depression+ anxiety4 (N=145) 
  
 
   
 
   
 
Pre 28.74 (9.16) 27.39 30.15 
0.59 
23.46 (12.27) 21.7 25.3 
0.41 
2.16 (0.65) 2.06 2.25 
0.45 
Post 22.46 (12.01) 20.7 24.22 18.51 (12.08) 16.74 20.29 1.85 (0.73) 1.74 1.97 
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1. Only one anxiety disorder according to the M.I.N.I. 2. Two or more anxiety disorders according to the M.I.N.I. and no mood disorder. 3. Only one depression disorder according to the 
M.I.N.I. 4. Depression and anxiety disorder according to the M.I.N.I. 
 
 
 
 
By number of diagnoses 
   
 
   
 
   
 
1 - 2 diagnoses (N=197)    
 
          
Pre 23.05 (9.50) 21.74 24.37 
0.54 
17.91 (10.47) 16.36 19.45 
0.44 
1.78 (0.61) 1.69 1.86 
0.39 
Post 17.16 (12.41) 15.61 18.71 13.34(10.25) 11.84 14.85 1.52 (0.72) 1.42 1.63 
3 plus diagnoses (N=84) 
   
 
   
 
   
 
Pre 29.22 (9.06) 27.19 31.25 
0.58 
26.19 (12.30) 23.80 28.58 
0.45 
2.24 (0.59) 2.12 2.38 
0.52 
Post 22.95  (12.41) 20.56 25.35 20.71(11.90) 18.39 23.04 1.90 (0.74) 1.75 2.06 
             Total (281) 
   
 
   
 
   
 
pre 24.88 (9.78) 23.73 26.03 
0.57 
20.35 (11.65) 18.98 21.72 
0.42 
1.92 (0.64) 1.84 2.00 
0.42 
post 18.87 (11.37) 17.53  20.21 15.52 (11.26) 14.20  16.84 1.64 (0.75) 1.55   1.73 
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Figure 1. Flow chart of the referral process.  
  
Referral 
Negative on substance abuse, 
psychosis or dementia. 
All treated. 
 N =441 
MINI at referral: 
Positive on depression or  any 
anxiety disorder. 
N =324 
Showed up for at least one treatment 
session. 
Final sample:  
N = 281 
BDI-II > 13 and/or 
BAI > 9 and/or 
CORE-OM > 1 
N =287 
Positive on substance abuse, 
psychosis or dementia. 
Excluded from treatment. 
MINI at referral: 
Negative on depression or  
any anxiety disorder. 
Excluded from data analysis. 
BDI-II ≤ 13 and/or 
BAI ≤ 9 and/or 
CORE-OM ≤ 1 
Excluded from data analysis. 
Did not show up for any 
treatment session. 
Excluded from data analysis. 
